Economic value and course of infection after treatment of cattle having a low level of nematode parasitism.
To determine whether it is economically advantageous to treat calves having inapparent parasitism, we conducted experiments from 1971 to 1976, involving more than 1,800 calves from 30 pens or lots, using formulations of thiabendazole, levamisole, and crufomate (ruelene). Differential egg counts, cultured larvae, and cultured parasitic stages were used to estimate the kind and degree of nematode parasitism. Differentiation of infective larvae consistently established Cooperia as the predominating (%) genus in all fecal samplings. Bunostomum, when initially present, decreased or disappeared, whereas Trichostrongylus increased; other genera fluctuated less consistently. These qualitative generic fluctuations were not primarily the result of treatment, but more likely were seasonal variation. Judged by average daily gain (ADG), anthelmintic treatment was statistically advantageous at one or more points during the observation periods in 10 of 13 treated groups. In seven treated groups, the observation periods were concluded with statistical advantage in ADG, whereas in three groups, compensatory gain by corresponding controls had neutralized earlier advantages. The comparative influence of the various anthelmintics was not consistent from year to year. When total cost/kilogram gain was calculated from feed efficiency measuremnts and other costs, economic treatment advantage was evident in seven of 11 tests (7 of 10 treatment groups) from 1973 through 1976. This financial advantage, due primarily to feed efficiency and noted after 28 to 51 days, justified anthelmintic treatment. This advantage was not likely lost by the animals in subsequent periods (to 218 days) on pasture or in lots, since ADG indicated the treated calves performed either as well as, or better than, the nontreated controls. Considering all aspects of the study, the results indicate calves coming into Kansas from southern states and weighing 184 to 267 kg may possess a level of subclinical (symptomless) nematode parasitism that when treated will result in a response justifying expense for using anthelmintics.
D000818:Animals; D002417:Cattle / Q000254:growth & development; D002418:Cattle Diseases / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D006188:Haemonchiasis / Q000188:drug therapy / Q000662:veterinary; D006725:Hookworm Infections / Q000188:drug therapy; D007978:Levamisole / Q000627:therapeutic use; D009349:Nematode Infections / Q000662:veterinary*; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010029:Ostertagiasis / Q000188:drug therapy / Q000662:veterinary; D013827:Thiabendazole / Q000627:therapeutic use; D014252:Trichostrongyloidiasis / Q000188:drug therapy / Q000662:veterinary
D009943:Organophosphorus Compounds; D007978:Levamisole; D013827:Thiabendazole